Skip to main content
Top
Published in: Digestive Diseases and Sciences 2/2023

16-11-2022 | Cytokines | Original Article

Clinical Efficacy of Tandospirone on Functional Dyspepsia Patients with Anxiety: A Randomized, Placebo-Controlled Study

Authors: Lulu Liu, Wenguang Yang, Ya Lu, Jue Wang, Yan Zheng, Sai Gu

Published in: Digestive Diseases and Sciences | Issue 2/2023

Login to get access

Abstract

Background

Functional dyspepsia (FD) is characterized with multiple symptoms of indigestion and often accompanied with anxiety. However, there is currently an absence of effective treatment. Tandospirone is commonly used to treat generalized anxiety disorders. Whether tandospirone can improve the clinical symptoms of FD remain unknown.

Aims

The present study was designed to explore the pharmacological effect of tandospirone on FD patient with anxiety, and the potential mechanisms were also elucidated.

Methods

FD patients with anxiety were randomly divided into placebo and tandospirone treatment groups. Healthy volunteers were simultaneously recruited as control group. The gastrointestinal symptom score (GIS) and Hamilton anxiety scale (HAM-A) were performed before and after treatments with placebo or tandospirone. The serum levels of brain-derived neurotrophic factor (BDNF) and multiple inflammatory cytokines including tumor necrosis factor-α (TNF-α), and interleukin (IL)-6, IL-4, IL-1β, and IL-10 were determined. Regression analyses relating BDNF levels and gastrointestinal symptoms were performed.

Results

Tandospirone significantly alleviated the gastrointestinal and anxiety symptoms of FD patient, as evidenced by reductions of GIS index and HAM-A scores. Compared with the healthy volunteers, FD patients had lower BDNF and IL-10 levels, but higher levels of IL-6 and TNF-α. Importantly, tandospirone increased serum BDNF and IL-10 and decreased IL-6 levels in FD patients. Relative analysis revealed that BDNF level was negatively associated with gastrointestinal symptoms in FD patients.

Conclusion

Tandospirone effectively improved both anxiety and gastrointestinal symptoms of patients with FD, and these therapeutic effects may be associated with the modulation of BDNF and inflammatory cytokines.
Literature
1.
go back to reference Ford AC, Mahadeva S, Carbone MF, Lacy BE, Talley NJ. Functional dyspepsia. Lancet 2020;396:1689–1702.CrossRef Ford AC, Mahadeva S, Carbone MF, Lacy BE, Talley NJ. Functional dyspepsia. Lancet 2020;396:1689–1702.CrossRef
2.
go back to reference Mounsey A, Barzin A, Rietz A. Functional Dyspepsia: Evaluation and Management. Am Fam Physician 2020;101:84–88. Mounsey A, Barzin A, Rietz A. Functional Dyspepsia: Evaluation and Management. Am Fam Physician 2020;101:84–88.
3.
go back to reference Oshima T, Miwa H. Epidemiology of Functional Gastrointestinal Disorders in Japan and in the World. J Neurogastroenterol Motil 2015;21:320–329.CrossRef Oshima T, Miwa H. Epidemiology of Functional Gastrointestinal Disorders in Japan and in the World. J Neurogastroenterol Motil 2015;21:320–329.CrossRef
4.
go back to reference Ly HG, Weltens N, Tack J, Van Oudenhove L. Acute Anxiety and Anxiety Disorders Are Associated With Impaired Gastric Accommodation in Patients With Functional Dyspepsia. Clin Gastroenterol Hepatol 2015;13:1584-1591.e3.CrossRef Ly HG, Weltens N, Tack J, Van Oudenhove L. Acute Anxiety and Anxiety Disorders Are Associated With Impaired Gastric Accommodation in Patients With Functional Dyspepsia. Clin Gastroenterol Hepatol 2015;13:1584-1591.e3.CrossRef
5.
go back to reference Van Oudenhove L, Aziz Q. The role of psychosocial factors and psychiatric disorders in functional dyspepsia. Nat Rev Gastroenterol Hepatol 2013;10:158–167.CrossRef Van Oudenhove L, Aziz Q. The role of psychosocial factors and psychiatric disorders in functional dyspepsia. Nat Rev Gastroenterol Hepatol 2013;10:158–167.CrossRef
6.
go back to reference Aro P, Talley NJ, Johansson SE, Agréus L, Ronkainen J. Anxiety Is Linked to New-Onset Dyspepsia in the Swedish Population: A 10-Year Follow-up Study. Gastroenterology 2015;148:928–937.CrossRef Aro P, Talley NJ, Johansson SE, Agréus L, Ronkainen J. Anxiety Is Linked to New-Onset Dyspepsia in the Swedish Population: A 10-Year Follow-up Study. Gastroenterology 2015;148:928–937.CrossRef
7.
go back to reference Miwa H, Nagahara A, Tominaga K et al. Efficacy of the 5-HT1A agonist tandospirone citrate in improving symptoms of patients with functional dyspepsia: a randomized controlled trial. Am J Gastroenterol 2009;104:2779–2787.CrossRef Miwa H, Nagahara A, Tominaga K et al. Efficacy of the 5-HT1A agonist tandospirone citrate in improving symptoms of patients with functional dyspepsia: a randomized controlled trial. Am J Gastroenterol 2009;104:2779–2787.CrossRef
8.
go back to reference Kinoshita Y, Hashimoto T, Kawamura A et al. Effects of famotidine, mosapride and tandospirone for treatment of functional dyspepsia. Aliment Pharmacol Ther 2005;21:37–41.CrossRef Kinoshita Y, Hashimoto T, Kawamura A et al. Effects of famotidine, mosapride and tandospirone for treatment of functional dyspepsia. Aliment Pharmacol Ther 2005;21:37–41.CrossRef
9.
go back to reference Kindt S, Van Oudenhove L, Broekaert D et al. Immune dysfunction in patients with functional gastrointestinal disorders. Neurogastroenterol Motil 2009;21:389–398.CrossRef Kindt S, Van Oudenhove L, Broekaert D et al. Immune dysfunction in patients with functional gastrointestinal disorders. Neurogastroenterol Motil 2009;21:389–398.CrossRef
10.
go back to reference Powell N, Walker MM, Talley NJ. The mucosal immune system: master regulator of bidirectional gut-brain communications. Nat Rev Gastroenterol Hepatol 2017;14:143–159.CrossRef Powell N, Walker MM, Talley NJ. The mucosal immune system: master regulator of bidirectional gut-brain communications. Nat Rev Gastroenterol Hepatol 2017;14:143–159.CrossRef
11.
go back to reference Phillips C. Brain-Derived Neurotrophic Factor, Depression, and Physical Activity: Making the Neuroplastic Connection. Neural Plast 2017;2017:7260130.CrossRef Phillips C. Brain-Derived Neurotrophic Factor, Depression, and Physical Activity: Making the Neuroplastic Connection. Neural Plast 2017;2017:7260130.CrossRef
12.
go back to reference Bus BA, Molendijk ML, Penninx BJ et al. Determinants of serum brain-derived neurotrophic factor. Psychoneuroendocrinology 2011;36:228–239.CrossRef Bus BA, Molendijk ML, Penninx BJ et al. Determinants of serum brain-derived neurotrophic factor. Psychoneuroendocrinology 2011;36:228–239.CrossRef
13.
go back to reference Satomura E, Baba H, Nakano Y, Maeshima H, Suzuki T, Arai H. Correlations between brain-derived neurotrophic factor and clinical symptoms in medicated patients with major depression. J Affect Disord 2011;135:332–335.CrossRef Satomura E, Baba H, Nakano Y, Maeshima H, Suzuki T, Arai H. Correlations between brain-derived neurotrophic factor and clinical symptoms in medicated patients with major depression. J Affect Disord 2011;135:332–335.CrossRef
14.
go back to reference Cheung C, Lan LL, Kyaw M et al. Up-regulation of transient receptor potential vanilloid (TRPV) and down-regulation of brain-derived neurotrophic factor (BDNF) expression in patients with functional dyspepsia (FD). Neurogastroenterol Motil 2018;30:e13176.CrossRef Cheung C, Lan LL, Kyaw M et al. Up-regulation of transient receptor potential vanilloid (TRPV) and down-regulation of brain-derived neurotrophic factor (BDNF) expression in patients with functional dyspepsia (FD). Neurogastroenterol Motil 2018;30:e13176.CrossRef
15.
go back to reference Tack J, Talley NJ. Functional dyspepsia–symptoms, definitions and validity of the Rome III criteria. Nat Rev Gastroenterol Hepatol 2013;10:134–141.CrossRef Tack J, Talley NJ. Functional dyspepsia–symptoms, definitions and validity of the Rome III criteria. Nat Rev Gastroenterol Hepatol 2013;10:134–141.CrossRef
16.
go back to reference Adam B, Liebregts T, Saadat-Gilani K, Vinson B, Holtmann G. Validation of the gastrointestinal symptom score for the assessment of symptoms in patients with functional dyspepsia. Aliment Pharmacol Ther 2005;22:357–363.CrossRef Adam B, Liebregts T, Saadat-Gilani K, Vinson B, Holtmann G. Validation of the gastrointestinal symptom score for the assessment of symptoms in patients with functional dyspepsia. Aliment Pharmacol Ther 2005;22:357–363.CrossRef
17.
go back to reference von Arnim U, Peitz U, Vinson B, Gundermann KJ, Malfertheiner P. STW 5, a phytopharmacon for patients with functional dyspepsia: results of a multicenter, placebo-controlled double-blind study. Am J Gastroenterol 2007;102:1268–1275.CrossRef von Arnim U, Peitz U, Vinson B, Gundermann KJ, Malfertheiner P. STW 5, a phytopharmacon for patients with functional dyspepsia: results of a multicenter, placebo-controlled double-blind study. Am J Gastroenterol 2007;102:1268–1275.CrossRef
18.
go back to reference Forssmann K, Meier L, Uehleke B, Breuer C, Stange R. A non-interventional, observational study of a fixed combination of pepsin and amino acid hydrochloride in patients with functional dyspepsia. BMC Gastroenterol 2017;17:123.CrossRef Forssmann K, Meier L, Uehleke B, Breuer C, Stange R. A non-interventional, observational study of a fixed combination of pepsin and amino acid hydrochloride in patients with functional dyspepsia. BMC Gastroenterol 2017;17:123.CrossRef
19.
go back to reference Hu P, Yang Q, Kong L, Hu L, Zeng L. Relationship between the anxiety/depression and care burden of the major caregiver of stroke patients. Medicine (Baltimore) 2018;97:e12638.CrossRef Hu P, Yang Q, Kong L, Hu L, Zeng L. Relationship between the anxiety/depression and care burden of the major caregiver of stroke patients. Medicine (Baltimore) 2018;97:e12638.CrossRef
20.
go back to reference Tse AW, Lai LH, Lee CC et al. Validation of Self-administrated Questionnaire for Psychiatric Disorders in Patients with Functional Dyspepsia. J Neurogastroenterol Motil 2010;16:52–60.CrossRef Tse AW, Lai LH, Lee CC et al. Validation of Self-administrated Questionnaire for Psychiatric Disorders in Patients with Functional Dyspepsia. J Neurogastroenterol Motil 2010;16:52–60.CrossRef
21.
go back to reference Koloski N, Holtmann G, Talley NJ. Is there a causal link between psychological disorders and functional gastrointestinal disorders. Expert Rev Gastroenterol Hepatol 2020;14:1047–1059.CrossRef Koloski N, Holtmann G, Talley NJ. Is there a causal link between psychological disorders and functional gastrointestinal disorders. Expert Rev Gastroenterol Hepatol 2020;14:1047–1059.CrossRef
22.
go back to reference Jones MP, Tack J, Van Oudenhove L et al. Mood and Anxiety Disorders Precede Development of Functional Gastrointestinal Disorders in Patients but Not in the Population. Clin Gastroenterol Hepatol 2017;15:1014-1020.e4.CrossRef Jones MP, Tack J, Van Oudenhove L et al. Mood and Anxiety Disorders Precede Development of Functional Gastrointestinal Disorders in Patients but Not in the Population. Clin Gastroenterol Hepatol 2017;15:1014-1020.e4.CrossRef
23.
go back to reference Black CJ, Houghton LA, Ford AC. Insights into the evaluation and management of dyspepsia: recent developments and new guidelines. Therap Adv Gastroenterol 2018;11:1756284818805597.CrossRef Black CJ, Houghton LA, Ford AC. Insights into the evaluation and management of dyspepsia: recent developments and new guidelines. Therap Adv Gastroenterol 2018;11:1756284818805597.CrossRef
24.
go back to reference Hojo M, Miwa H, Yokoyama T et al. Treatment of functional dyspepsia with antianxiety or antidepressive agents: systematic review. J Gastroenterol 2005;40:1036–1042.CrossRef Hojo M, Miwa H, Yokoyama T et al. Treatment of functional dyspepsia with antianxiety or antidepressive agents: systematic review. J Gastroenterol 2005;40:1036–1042.CrossRef
25.
go back to reference Xiong N, Duan Y, Wei J, Mewes R, Leonhart R. Antidepressants vs. Placebo for the Treatment of Functional Gastrointestinal Disorders in Adults: A Systematic Review and Meta-Analysis. Front Psychiatry. 2018;9:659.CrossRef Xiong N, Duan Y, Wei J, Mewes R, Leonhart R. Antidepressants vs. Placebo for the Treatment of Functional Gastrointestinal Disorders in Adults: A Systematic Review and Meta-Analysis. Front Psychiatry. 2018;9:659.CrossRef
26.
go back to reference Cubeddu A, Bucci F, Giannini A et al. Brain-derived neurotrophic factor plasma variation during the different phases of the menstrual cycle in women with premenstrual syndrome. Psychoneuroendocrinology 2011;36:523–530.CrossRef Cubeddu A, Bucci F, Giannini A et al. Brain-derived neurotrophic factor plasma variation during the different phases of the menstrual cycle in women with premenstrual syndrome. Psychoneuroendocrinology 2011;36:523–530.CrossRef
27.
go back to reference Molendijk ML, Bus BA, Spinhoven P et al. Serum levels of brain-derived neurotrophic factor in major depressive disorder: state-trait issues, clinical features and pharmacological treatment. Mol Psychiatry 2011;16:1088–1095.CrossRef Molendijk ML, Bus BA, Spinhoven P et al. Serum levels of brain-derived neurotrophic factor in major depressive disorder: state-trait issues, clinical features and pharmacological treatment. Mol Psychiatry 2011;16:1088–1095.CrossRef
28.
go back to reference Bath KG, Chuang J, Spencer-Segal JL et al. Variant brain-derived neurotrophic factor (Valine66Methionine) polymorphism contributes to developmental and estrous stage-specific expression of anxiety-like behavior in female mice. Biol Psychiatry 2012;72:499–504.CrossRef Bath KG, Chuang J, Spencer-Segal JL et al. Variant brain-derived neurotrophic factor (Valine66Methionine) polymorphism contributes to developmental and estrous stage-specific expression of anxiety-like behavior in female mice. Biol Psychiatry 2012;72:499–504.CrossRef
29.
go back to reference Bergami M, Rimondini R, Santi S, Blum R, Götz M, Canossa M. Deletion of TrkB in adult progenitors alters newborn neuron integration into hippocampal circuits and increases anxiety-like behavior. Proc Natl Acad Sci USA 2008;105:15570–15575.CrossRef Bergami M, Rimondini R, Santi S, Blum R, Götz M, Canossa M. Deletion of TrkB in adult progenitors alters newborn neuron integration into hippocampal circuits and increases anxiety-like behavior. Proc Natl Acad Sci USA 2008;105:15570–15575.CrossRef
30.
go back to reference Dutt R, Shankar N, Srivastava S, Yadav A, Ahmed RS. Cardiac autonomic tone, plasma BDNF levels and paroxetine response in newly diagnosed patients of generalised anxiety disorder. Int J Psychiatry Clin Pract 2020;24:135–142.CrossRef Dutt R, Shankar N, Srivastava S, Yadav A, Ahmed RS. Cardiac autonomic tone, plasma BDNF levels and paroxetine response in newly diagnosed patients of generalised anxiety disorder. Int J Psychiatry Clin Pract 2020;24:135–142.CrossRef
31.
go back to reference Wang Y, Zhang H, Li Y et al. BDNF Val66Met polymorphism and plasma levels in Chinese Han population with obsessive-compulsive disorder and generalized anxiety disorder. J Affect Disord 2015;186:7–12.CrossRef Wang Y, Zhang H, Li Y et al. BDNF Val66Met polymorphism and plasma levels in Chinese Han population with obsessive-compulsive disorder and generalized anxiety disorder. J Affect Disord 2015;186:7–12.CrossRef
32.
go back to reference Molendijk ML, Bus BA, Spinhoven P et al. Gender specific associations of serum levels of brain-derived neurotrophic factor in anxiety. World J Biol Psychiatry 2012;13:535–543.CrossRef Molendijk ML, Bus BA, Spinhoven P et al. Gender specific associations of serum levels of brain-derived neurotrophic factor in anxiety. World J Biol Psychiatry 2012;13:535–543.CrossRef
33.
go back to reference Carlino D, Francavilla R, Baj G et al. Brain-derived neurotrophic factor serum levels in genetically isolated populations: gender-specific association with anxiety disorder subtypes but not with anxiety levels or Val66Met polymorphism. PeerJ 2015;3:e1252.CrossRef Carlino D, Francavilla R, Baj G et al. Brain-derived neurotrophic factor serum levels in genetically isolated populations: gender-specific association with anxiety disorder subtypes but not with anxiety levels or Val66Met polymorphism. PeerJ 2015;3:e1252.CrossRef
34.
go back to reference Keely S, Walker MM, Marks E, Talley NJ. Immune dysregulation in the functional gastrointestinal disorders. Eur J Clin Invest. 2015;45:1350–1359.CrossRef Keely S, Walker MM, Marks E, Talley NJ. Immune dysregulation in the functional gastrointestinal disorders. Eur J Clin Invest. 2015;45:1350–1359.CrossRef
35.
go back to reference Aro P, Talley NJ, Ronkainen J et al. Anxiety is associated with uninvestigated and functional dyspepsia (Rome III criteria) in a Swedish population-based study. Gastroenterology 2009;137:94–100.CrossRef Aro P, Talley NJ, Ronkainen J et al. Anxiety is associated with uninvestigated and functional dyspepsia (Rome III criteria) in a Swedish population-based study. Gastroenterology 2009;137:94–100.CrossRef
36.
go back to reference Koloski NA, Jones M, Kalantar J, Weltman M, Zaguirre J, Talley NJ. The brain–gut pathway in functional gastrointestinal disorders is bidirectional: a 12-year prospective population-based study. Gut 2012;61:1284–1290.CrossRef Koloski NA, Jones M, Kalantar J, Weltman M, Zaguirre J, Talley NJ. The brain–gut pathway in functional gastrointestinal disorders is bidirectional: a 12-year prospective population-based study. Gut 2012;61:1284–1290.CrossRef
Metadata
Title
Clinical Efficacy of Tandospirone on Functional Dyspepsia Patients with Anxiety: A Randomized, Placebo-Controlled Study
Authors
Lulu Liu
Wenguang Yang
Ya Lu
Jue Wang
Yan Zheng
Sai Gu
Publication date
16-11-2022
Publisher
Springer US
Keywords
Cytokines
Anxiety
Published in
Digestive Diseases and Sciences / Issue 2/2023
Print ISSN: 0163-2116
Electronic ISSN: 1573-2568
DOI
https://doi.org/10.1007/s10620-022-07717-z

Other articles of this Issue 2/2023

Digestive Diseases and Sciences 2/2023 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine